← Back to Search

Other

Parental Medication Education for Preventing Medication Errors After NICU Discharge

N/A

Recruiting

Led By Hsiang Sharon Yin

Research Sponsored by NYU Langone Health

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Child discharged home with a Rx for >1 daily liquid medication (other than multivitamin)

18 years of age and older

Timeline

Screening 3 weeks

Treatment Varies

Follow Up visit 3 (day 30)

Awards & highlights

Study Summary

This trial is testing whether a program to educate parents of children in the Neonatal Intensive Care Unit (NICU) about their child's care after discharge decreases the number of readmissions to the NICU.

Who is the study for?

This trial is for parents over 18, who speak English or Spanish, and are the primary caregivers administering at least one daily liquid medication to their child after discharge from the neonatal intensive care unit. Participants must have internet access, a mobile phone that can receive texts, and be able to return for follow-up visits.Check my eligibility

What is being tested?

The study compares two methods of helping parents safely give medications: HELPix+Tech (a technology-based aid) versus HELPix alone. It's designed to see which method reduces medication errors after infants leave the hospital.See study design

What are the potential side effects?

Since this trial focuses on educational interventions rather than medical treatments, there are no direct side effects related to drugs or therapies being tested.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My child was sent home with a prescription for daily liquid medication.

Select...

I am 18 years old or older.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ visit 3 (day 30)

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~visit 3 (day 30)

This trial's timeline: 3 weeks for screening, Varies for treatment, and visit 3 (day 30) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Improvement in Dosing with HELPix+TECH and HELPix in comparison to usual care.

Improvement in medication adherence with HELPix+TECH and HELPix in comparison to usual care

Trial Design

3Treatment groups

Experimental Treatment

Active Control

Group I: HELPix+TechExperimental Treatment1 Intervention

After parent receives usual care and HELPix (as above), trained staff will walk parent through the app on-boarding process to overcome initial barriers to use. Steps: 1) Parent texted link to personalized on-line instructions. 2) Parent clicks link to app

Group II: HELPixExperimental Treatment1 Intervention

HELPix parents will receive usual care as above, after which trained staff will generate HELPix patient-/regimen-specific medication instruction sheets and review them with the parent.

Group III: Usual CareActive Control1 Intervention

Current usual care includes standard discharge counseling by a nurse, with or without additional MD counseling.

0 / 2Eligibility criteria met

Find a Location

Who is running the clinical trial?

NYU Langone HealthLead Sponsor

1,368 Previous Clinical Trials

839,301 Total Patients Enrolled

3 Trials studying Medication Errors

2,452 Patients Enrolled for Medication Errors

Hsiang Sharon YinPrincipal InvestigatorNYU Langone

Media Library

HELPix (Other) Clinical Trial Eligibility Overview. Trial Name: NCT04278690 — N/A

Medication Errors Research Study Groups: HELPix+Tech, Usual Care, HELPix

Medication Errors Clinical Trial 2023: HELPix Highlights & Side Effects. Trial Name: NCT04278690 — N/A

HELPix (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT04278690 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What is the aggregate population for this investigation?

"Affirmative, the clinicaltrials.gov platform reveals that this trial is presently accepting new patients for enrollment. This study was initially posted on March 10th 2021 and edited last on November 9th 2022; 450 individuals are sought from one site of research."

Answered by AI

Is this medical experiment currently accepting new participants?

"Yes, as evidenced by the clinicaltrials.gov's data, this trial is actively seeking participants. Initially posted on March 10th 2021, it was last updated on November 9th 2022 and requires 450 volunteers from a single site."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Supporting Safe Use of Medications by Parents After Infant Discharge From the Neonatal Intensive Care Unit

2021. "Supporting Safe Use of Medications by Parents After Infant Discharge From the Neonatal Intensive Care Unit". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04278690.